CA-MAANA
29.3.2021 16:02:10 CEST | Business Wire | Press release
Airbus Commercial and Maana today announced Airbus Cognitive Platform (“AIRKOG”) that is capable of answering any domain-specific question.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005119/en/
“As a transformational platform, AIRKOG is helping us to drive improvements at Airbus Commercial,” said Florent Bouix, AIRKOG Platform Manager for Big Data products service line at Airbus. “We provide solutions to thousands of employees with an increasing number of intelligent applications in engineering, procurement, logistics, quality, program management, as well as rapid analysis for plant and final assembly line improvements.”
Using AIRKOG platform capabilities, Airbus consolidates data from tens of different systems; identifies and establishes a vast number of relations and correlations, implement computations and run analysis across multiple operational domains; all on a single platform.
“Thanks to AIRKOG, we achieved multi-million Euro cost savings per year at various areas,” Mr. Bouix stated “for example:
- Managing complex process related to new parts introduction due to aircraft changes for new Head of Version (involving engineering, sourcing, ordering, and manufacturing),
- Supporting the margin reviews or costs reduction of some aircraft options,
- Mastering electrical harnesses configuration changes and reallocation by providing multivariate analysis to avoid scrapping in a complex manufacturing organization with multiple plants.”
AIRKOG started in 2017 as a proof of concept for use of knowledge graph technology to reduce time spent by Airbus engineers and technicians searching for information. AIRKOG moved to pilot phase in 2018, and into production in 2019. After two years running in production at scale, Airbus Commercial and Maana extended their partnership for another three years for 2021-2023.
“AIRKOG is an intelligent platform, like its consumer-facing cousins Siri and Alexa,” said Babur Ozden, Founder and CEO of Maana. “However, it answers far more difficult questions regarding many complex aspects of making, maintaining, and repairing aircraft.”
“Thanks to AIRKOG platform and the computational knowledge graph at its core, we reduced costs by 20% - 30% and lead-time for analysis by 30% - 75% on our digitalization platform” said Marc Monties, WideBody digitalization plateau leader at Airbus.
About Airbus Commercial Aircraft
Airbus is a leading aircraft manufacturer whose customer focus, commercial know-how, technological leadership and manufacturing efficiency have propelled it to the forefront of the aviation and air transport industries. The company’s mission is to provide jetliners that are best-suited to the market's needs and to support them with the highest quality of service.
About Maana
Maana organizes human expertise, enterprise knowhow and industrial data into digital knowledge to assist subject matter experts at critical operation affecting the global economy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom